NET clinical trails contact
For NET clinical trial enquiry, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
We also acknowledge the importance of consumer engagement in shaping and improving NET research and care. If this sounds like something you would like to get involve in, further information is available from Consumer and Community Engagement.
- 10/119: Genetic Analysis of Familial Phaeochromocytoma by Next Generation Sequencing
- The PLANET Registry: An Observational, Multi-centre, Non-Interventional Programme to Register Patients Diagnosed With Neuroendocrine Neoplasms (NENs) and Monitor Their Patterns of Care in Australian Hospitals
- NET SANGUIS: The potential role of circulating DNA in the management of pancreatic neuroendocrine tumours
- PARLuNET: Phase 1 trial of PARP Inhibitor combined with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic NeuroEndocrine Tumor (NCT05053854)
- COMPOSE: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (NCT04919226)
- GoTHAM: A Phase 1b/2 Study of Combination Avelumab with Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients with Metastatic Merkel Cell Carcinoma (NCT04261855)
- I-CHROME: Investigating Clonal Haematopoiesis and Risk factors for Myeloid neoplasia. This study is now open for recruitment.
- ABBV-706: A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors (including high grade NEC / NETs). (NCT05599984)
- COMPETE: Phase 3 Study to Evaluate Efficacy & Safety of PRRT & 177 Luedotreotide Compared to Everolimus in Patients with Inoperable, Progressive, SSTR+ GEPNET (NCT03049189)
- DISCO: Positron Emission Tomography Imaging of Participants with Known or Suspected Gastroenteropancreatic Neuroendocrine Tumours Using 64Cu-SARTATE: A Multi-Centre, Single Arm, Non-Randomised, Blinded-Review, Phase II study (NCT04438304)
- IPSEN Safety: A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 (NCT05017662)
- 10/116: Analysis of Imaging Phenotypes and Genotypes in Neuroendocrine Tumours undergoing
- peptide-based radionuclide therapy
- MOST-CIRCUIT: Combination Immunotherapy in Rare Cancers Under InvesTigation (NCT04969887)
- BAYONET: Influence of LA SSA on GaTate PET/CT – baseline, reproducible, post SSA scan (Day4±1)
- STOPNET: A randomised study of cessation of somatostatin analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Neuroendocrine tumours (NCT06345079)
- AUS-NET: Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours – a randomised-controlled type II hybrid effectiveness-implementation trial
